Vaccines manufactured at Moderna’s state-of-the-art Canadian mRNA facility to be prepared and packaged at Novocol’s Ontario-based facility
Fill-finish agreement will secure domestic end-to-end vaccine production and ensures rapid response capabilities for future pandemic readiness for Canadians
TORONTO-Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines, today announced a long-term agreement with Ontario-based Novocol Pharma, a leading sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines expected to be produced in Canada. Fill-finish sterile manufacturing is the final step in the production cycle and includes transferring the vaccine drug product into vials and packaging them for use.
The agreement with Novocol Pharma will result in the fill-finish capacity of vaccines manufactured at Moderna’s Laval-based mRNA facility, which is expected to become operational by the end of 2024, subject to planning and regulatory approvals. To assist with the creation of highly sophisticated manufacturing capabilities necessary to fill and finish the mRNA vaccines, the Government of Ontario, through the Ontario Together Fund, has provided a grant to Moderna. Moderna’s partnership with Novocol Pharma also supports the Government of Canada’s strategic investments under Canada’s Biomanufacturing and Life Sciences Strategy to provide onshore respiratory vaccine manufacturing capabilities and support national pandemic readiness for all Canadians.
The agreement also expands Moderna’s footprint and investment in Ontario to help make mRNA vaccines available for all Canadians and to support high-skilled jobs in this growing sector. Together with the new facility in Laval and partnerships with local universities and biotech start-ups, Moderna is helping to drive Canada’s position as an mRNA centre of excellence. Moderna’s mRNA pipeline includes 47 programs, including vaccines against respiratory viruses, vaccines against latent viruses, and vaccines against threats to global public health.
“Canada’s scientific expertise and biomanufacturing capabilities make it a key and strategic country for Moderna as we expand our mRNA technology capabilities globally. Novocol Pharma exemplifies best-inclass experience, capabilities, manufacturing systems, and controls required to prepare our mRNA vaccines and scale up production as needed to address novel or emerging viruses.” Jerh Collins, Chief Technical Operations and Quality Officer, Moderna
“Moderna is pleased to be growing a bigger presence in Ontario through our agreement with Novocol Pharma, thanks in part to the important contribution from the Government of Ontario. Today’s announcement complements our activities in Quebec and contributes to Moderna’s long-term partnership with the Federal Government to provide onshore respiratory vaccine manufacturing capabilities and support national pandemic readiness for all Canadians.” Patricia Gauthier, President and General Manager of Moderna Canada.
“Novocol Pharma, a Septodont company, is honored to be Moderna’s fill-finish partner for domestic production of vaccines. Our partnership is a synergy of capabilities between our respective organizations. Together, we will strengthen Canada’s domestic supply chain for the production of vaccines and pandemic preparedness. This achievement has been made possible through collaboration between the private and the public sector, at both provincial and federal levels.” Atif Zia, CEO of Septodont and President of Novocol Pharma.